Clinical Trial Update: Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). [Phase 1, Phase 2]

View source ↗

Summary

Thryv Therapeutics' Phase 1/2 study of LQT-1213 to assess QTc prolongation in healthy adults and in patients with congenital Long QT syndrome (types 2 and 3) wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Qt Syndrome

Drugs mentioned

• LQT-1213

Snippet

Sponsor: Thryv Therapeutics, Inc. | Conditions: Long QT Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-07-24